Immunological response against bone and soft tissue sarcoma
Project/Area Number |
22689041
|
Research Category |
Grant-in-Aid for Young Scientists (A)
|
Allocation Type | Single-year Grants |
Research Field |
Orthopaedic surgery
|
Research Institution | Sapporo Medical University |
Principal Investigator |
|
Project Period (FY) |
2010 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥25,610,000 (Direct Cost: ¥19,700,000、Indirect Cost: ¥5,910,000)
Fiscal Year 2011: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
Fiscal Year 2010: ¥13,650,000 (Direct Cost: ¥10,500,000、Indirect Cost: ¥3,150,000)
|
Keywords | 骨 / 軟部腫瘍学 / 骨肉腫抗原 / HLA/ペプチド複合体 / ファージディスプレイライブラリ |
Research Abstract |
We performed phase I clinical peptide vaccination trial for patient with osteosarcoma. We used HLA-A24 or HLA-A2-restricted PBF-derived peptides as the vaccines with incomplete Freund' adjuvant. The peptide-specific CTL responses were observed in two HLA-A24+ and one HLA-A2+patients. After the confirmation of safety and immunogenicity of the peptide vaccines, we will plan phase II trial as adjuvant therapy after operative resection combined with post-operative chemotherapy. In addition, we generated artificial antibody against HLA/peptide complex recognized by CTL(natural epitope antibody). scFv phage display library was constructed from RNA derived from human naive PBMC and tonsiles, followed by biopanning using HLA-A2/PBF peptide complex. After panning, one scFv clone was obtained and converted into hIgG1 subtype(scFv-hIgG1). The scFv-hIgG1 recognized peptide-pulsed T2 cells by FACS and showed high affinity by SPR analysis. This natural epitope antibody might be useful for the detection of HLA/peptide complex on tumor cells and for the development of genetically engineered CTLs expressing natural epitope antibody for adoptive cell therapy.
|
Report
(3 results)
Research Products
(17 results)
-
[Journal Article] ECRG4 is a negative regulator of caspase-8-mediated apoptosis in human T-leukemia cells2012
Author(s)
Matsuzaki J,Torigoe T,Hirohashi Y, Kamiguchi K,Tamura Y, Tsukahara T,Kubo T, Takahashi A, Nakazawa E,Saka E, Yasuda K,Takahashi S,Sato N.
-
Journal Title
Carcinogenesis
Volume: 33
Issue: 5
Pages: 996-1003
DOI
Related Report
Peer Reviewed
-
[Journal Article] Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma2011
Author(s)
Kano, M., Tsukahara, T., Emori, M., Murase, M., Torigoe, T., Kawaguchi, S., Wada, T., Yamashita, T., Sato, N.
-
Journal Title
Cancer Sci
Volume: 102
Issue: 8
Pages: 1443-1137
DOI
NAID
Related Report
Peer Reviewed
-
[Journal Article] Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors2011
Author(s)
Yabe H, Tsukahara T, Kawaguchi S, Wada T, Torigoe T, Sato N, Terai C, Aoki M, Hirose S, Morioka H, Yabe H
-
Journal Title
J Surg Oncol
Volume: 103
Issue: 5
Pages: 380-385
DOI
Related Report
Peer Reviewed
-
[Journal Article] Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients2011
Author(s)
Kameshima, H., Tsuruma, T., Torigoe, T., Takahashi, A., Hirohashi, Y., Tamura, Y., Tsukahara, T., Ichimiya, S., Kanaseki, T., Iwayama, Y., Sato, N., Hirata, K.
-
Journal Title
Cancer Sci
Volume: 102
Issue: 6
Pages: 1181-1187
DOI
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Development of peptide vaccination therapy targeting apoptosis regulator protein PBF for patients with osteosarcoma2010
Author(s)
Tomohide Tsukahara, Satoshi Kawaguchi, Toshihiko Torigoe, Shingo Ichimiya, Masanobu Kano, Akari Takahashi, Satoshi Nagoya, Takuro Wada, Toshihiko Yamashita, Noriyuki Sato
Organizer
Immunology : 2010
Place of Presentation
Kobe, Japan
Related Report
-
-